Resona Asset Management Co. Ltd. Purchases New Position in Amgen Inc. (NASDAQ:AMGN)

Resona Asset Management Co. Ltd. purchased a new stake in shares of Amgen Inc. (NASDAQ:AMGN) in the 4th quarter, Holdings Channel.com reports. The firm purchased 166,691 shares of the medical research company’s stock, valued at approximately $43,494,000.

A number of other large investors have also added to or reduced their stakes in the company. Centricity Wealth Management LLC bought a new stake in Amgen in the fourth quarter worth $25,000. Legacy Investment Solutions LLC purchased a new position in shares of Amgen in the 3rd quarter worth $29,000. Synergy Investment Management LLC bought a new stake in shares of Amgen in the 4th quarter worth about $34,000. Atala Financial Inc purchased a new stake in shares of Amgen during the 4th quarter valued at about $34,000. Finally, Heck Capital Advisors LLC bought a new position in shares of Amgen in the 4th quarter valued at about $36,000. Institutional investors own 76.50% of the company’s stock.

Insider Transactions at Amgen

In other news, EVP Murdo Gordon sold 8,771 shares of the company’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $294.79, for a total transaction of $2,585,603.09. Following the transaction, the executive vice president now owns 44,186 shares in the company, valued at $13,025,590.94. This represents a 16.56 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Nancy A. Grygiel sold 1,589 shares of the business’s stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the sale, the senior vice president now directly owns 7,210 shares in the company, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 69,341 shares of company stock valued at $20,644,335. Corporate insiders own 0.69% of the company’s stock.

Amgen Trading Down 5.0 %

AMGN opened at $294.39 on Friday. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. The firm has a market cap of $158.15 billion, a price-to-earnings ratio of 38.99, a PEG ratio of 2.63 and a beta of 0.53. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85. The stock has a fifty day moving average price of $304.18 and a 200-day moving average price of $297.49.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping analysts’ consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. As a group, equities research analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be issued a $2.38 dividend. This represents a $9.52 annualized dividend and a yield of 3.23%. The ex-dividend date of this dividend is Friday, May 16th. Amgen’s dividend payout ratio is currently 126.09%.

Wall Street Analyst Weigh In

AMGN has been the subject of a number of recent research reports. Wells Fargo & Company reiterated an “equal weight” rating on shares of Amgen in a report on Wednesday, February 5th. StockNews.com upgraded shares of Amgen from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 29th. Truist Financial reduced their price objective on shares of Amgen from $333.00 to $298.00 and set a “hold” rating on the stock in a research report on Wednesday, January 8th. Citigroup reissued a “neutral” rating on shares of Amgen in a research note on Wednesday, February 5th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $324.00 target price on shares of Amgen in a research note on Friday, January 24th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Amgen presently has an average rating of “Moderate Buy” and an average price target of $314.04.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.